EMA adopts positive opinion for Keytruda in melanoma following complete resection

Source: The Cancer Letter, May 2022

A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.

READ THE ORIGINAL FULL ARTICLE